ReviewNature reviews. Nephrology2011
The podocyte as a target for therapies--new and old.
Review in Nature reviews. Nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05875454 (Assessment of Podocyts Integrity in Glomerular Diseases.), which is not on this map. Cited by 80 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Podocyts Integrity in Glomerular Diseases.
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- Evolutionary patterns and research frontiers in autophagy in podocytopathies: a bibliometric analysis.Frontiers in medicine · 2024Pooled it
- Low-intensity extracorporeal shockwave therapy in patients with diabetic kidney disease: a matched cohort study.International urology and nephrology · 2025Trial
- High burden of kidney involvement in neuronal intranuclear inclusion disease.Frontiers in neurology · 2026Article
- Association of the C-Reactive Protein-Triglyceride-Glucose Index with Kidney Injury in Patients with Coronary Heart Disease: A Two-Center Cross-Sectional Study.Journal of inflammation research · 2026Article
- SSB deficiency-induced R-loop accumulation triggers podocyte inflammation in DKD.Frontiers in immunology · 2026Article
- TangNaikang Formula Alleviates Podocyte Injury in Diabetic Nephropathy by Modulating the SHIP2/PI3K/AKT Pathway.Journal of diabetes research · 2025Article
- Epigallocatechin-3-Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL-1β Signaling Pathway.Food science & nutrition · 2024Article
- Fiery Connections: Macrophage-Mediated Inflammation, the Journey from Obesity to Type 2 Diabetes Mellitus and Diabetic Kidney Disease.Biomedicines · 2024Review
- RNA-Seq-Based Transcriptome Analysis of Chinese Cordyceps Aqueous Extracts Protective Effect against Adriamycin-Induced mpc5 Cell Injury.International journal of molecular sciences · 2024Article
- "Qi Nan" agarwood restores podocyte autophagy in diabetic kidney disease by targeting EGFR signaling pathway.Chinese medicine · 2024Article
- Spice Up Your Kidney: A Review on the Effects of Capsaicin in Renal Physiology and Disease.International journal of molecular sciences · 2024Review
- Cytoskeleton Rearrangement in Podocytopathies: An Update.International journal of molecular sciences · 2024Review
- The fate of immune complexes in membranous nephropathy.Frontiers in immunology · 2024Review
- Glomerular injury after trauma, burn, and sepsis.Journal of nephrology · 2023Review
- Emodin Ameliorates High Glucose-Induced Podocyte Apoptosis via Regulating AMPK/mTOR-Mediated Autophagy Signaling Pathway.Chinese journal of integrative medicine · 2023Article
- Containing anti-PLA2R IgG antibody induces podocyte injury in idiopathic membranous nephropathy.Renal failure · 2023Article
- BM-MSCs alleviate diabetic nephropathy in male rats by regulating ER stress, oxidative stress, inflammation, and apoptotic pathways.Frontiers in pharmacology · 2023Article
- Angiopoietin-like protein 3: a novel potential biomarker for nephrotic syndrome in children.Frontiers in pediatrics · 2023Article
- Flot2 acts as a novel mediator of podocyte injury in proteinuric kidney disease.International journal of biological sciences · 2023Article
- miRNA-93-5p in exosomes derived from M2 macrophages improves lipopolysaccharide-induced podocyte apoptosis by targeting Toll-like receptor 4.Bioengineered · 2022Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Injury to the podocyte results in proteinuria and often leads to progressive kidney disease. As podocytes have limited ability to repair and/or regenerate, the extent of podocyte injury is a major prognostic determinant in diabetic nephropathy and other common causes of end-stage renal disease. Therapies aimed at preventing or limiting podocyte injury and/or at promoting podocyte repair or regeneration therefore have major potential clinical and economic benefits. Many current therapies--including glucocorticosteroids and calcineurin antagonists--have potent effects on podocytes. The nonspecific natures of these agents lead to undesirable systemic adverse effects: an agent with a more specific focus on podocytes would cause less treatment-associated morbidity. Recent years have seen dramatic advances in our understanding of podocyte biology and in particular regulation of its actin cytoskeleton, the major determinant of the complex architecture on which these cells depend for their function. This advance has allowed the identification of potential therapeutic targets and the next few years should see the development and testing of specific therapies aimed at the podocyte. Thus we are about to move from a situation where some of our 'blunderbuss' older therapies fortuitously happened to have beneficial effects on podocytes to a new era where advances in biological knowledge about a key cell type in the kidney will allow targeted drug design. As well as being intellectually more satisfying, every reason exists to believe that patients of the future will benefit and that the scourge of progressive kidney disease will be more effectively tackled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.